Hims & Hers Stock Rallies After Ceasing GLP-1 Compounding in Lilly Deal

Hims & Hers Health Inc., the prominent telehealth platform, confirmed today that it has reached an agreement with pharmaceutical giant Eli Lilly. As part of this new arrangement, Hims & Hers will cease compounding GLP-1 medications, including formulations designed to mimic Lilly’s blockbuster drug, Zepbound.

The announcement, made on Friday, 6 November 2026, has been met with a strong positive reaction from investors, sending Hims & Hers stock rallying. This strategic pivot signals a significant shift in the company's approach to the rapidly expanding market for weight-loss and diabetes treatments.

Why Hims & Hers is Changing its GLP-1 Strategy

The agreement marks a crucial development for Hims & Hers, which has been offering compounded versions of GLP-1 (glucagon-like peptide-1) agonists through its platform. Compounding involves pharmacists creating custom medications for individual patients, often using active ingredients from approved drugs but in different forms or combinations. While legal under specific circumstances, compounded versions of popular drugs like Zepbound and Novo Nordisk's Ozempic have faced scrutiny from pharmaceutical manufacturers and regulators regarding their safety, efficacy, and intellectual property.

Eli Lilly, like other pharmaceutical innovators, has been vocal about protecting its patented formulations and ensuring patients receive FDA-approved treatments. The company has previously taken legal action against entities selling compounded versions of its GLP-1 drugs, arguing that these products lack the rigorous testing and oversight of their branded counterparts. This agreement with Hims & Hers suggests a move towards industry-wide clarity regarding the distribution of these highly sought-after medications.

For Hims & Hers, this decision likely de-risks its business model in the long term. While compounded drugs can offer a cost-effective alternative, they expose providers to potential legal challenges and reputational damage. Shifting away from compounding allows the company to focus on distributing branded, FDA-approved medications, potentially through partnerships or direct supply agreements with manufacturers.

The Booming GLP-1 Market and Regulatory Landscape

GLP-1 agonists have revolutionized the treatment of type 2 diabetes and obesity, offering significant weight loss benefits. Drugs like Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) have seen unprecedented demand, leading to supply shortages and a surge in interest for alternative access routes, including compounded versions.

The global market for these drugs is projected to reach hundreds of billions of dollars in the coming years, attracting intense competition and regulatory attention. As we reported in Eli Lilly Raises Outlook as Zepbound Dominates Weight-Loss Drug Market, Lilly has been aggressively expanding production and defending its market position.

Regulators, including the U.S. Food and Drug Administration (FDA), have issued warnings about the risks associated with compounded GLP-1 drugs, particularly those using unapproved active pharmaceutical ingredients or prepared in facilities that do not meet strict quality standards. This regulatory environment has put pressure on telehealth providers and pharmacies offering these alternatives.

What This Means for Hims & Hers Health and Investors

For Hims & Hers, this agreement represents a significant strategic pivot. The company, known for its direct-to-consumer model for various health and wellness products, including those for hims hers hair growth, skin care, and sexual health, has increasingly ventured into chronic condition management. Its foray into GLP-1s through compounding was an attempt to capture a share of this lucrative market.

By discontinuing compounding, Hims & Hers is signaling a commitment to a more traditional, regulated pharmaceutical supply chain. This could pave the way for formal partnerships with manufacturers like Eli Lilly or other pharmaceutical companies, allowing them to offer branded GLP-1s directly to patients. Such a move would likely be viewed positively by investors, as it reduces regulatory uncertainty and aligns the company with established industry practices.

The market's reaction, with hims hers stock rallying, underscores investor confidence that this agreement will ultimately benefit the company. It suggests that the market believes the long-term gains from regulatory certainty and potential manufacturer partnerships outweigh any short-term impact from ceasing compounded drug sales. The Nasdaq, where Hims & Hers is listed, saw a gain of 1.43% today, reflecting a broader positive sentiment in the tech-heavy market.

Implications for Consumers and the Telehealth Sector

For consumers, especially those in Nigeria, the rest of Africa, and globally who rely on telehealth platforms for access to medication, this development highlights the evolving landscape of drug delivery. While compounded drugs sometimes offer lower prices, the shift towards branded medications through platforms like Hims & Hers could mean greater assurance of product quality and safety, albeit potentially at a higher cost.

This agreement could also influence other telehealth providers. It sets a precedent that major pharmaceutical companies are actively engaging with and potentially integrating telehealth platforms into their distribution strategies, rather than simply pursuing legal action. This could lead to a more formalized and regulated approach to medication access through digital channels across the industry.

Questions remain about how Hims & Hers will replace the revenue stream from compounded GLP-1s. The company may seek to expand its offerings of other FDA-approved medications or deepen its existing relationships with pharmaceutical partners. This strategic realignment could also protect the company from potential hims hers lawsuit risks related to compounded medications, strengthening its overall market position.

What to watch

• Hims & Hers' Q4 2026 Earnings Call: Investors will be keen to hear management's detailed strategy for GLP-1 offerings and revenue projections in light of this agreement.
• Further Partnerships: Monitor for announcements of new supply agreements or collaborations between Hims & Hers and pharmaceutical manufacturers for branded GLP-1 drugs.
• Regulatory Updates: Keep an eye on any new guidance from the FDA or other health authorities regarding compounded medications and telehealth practices.
• Competitor Responses: Observe how other telehealth companies adjust their strategies in the GLP-1 market following this precedent-setting deal.